Table 1.
Disease | CoQ10 Application | References |
---|---|---|
Diabetic cardiovascular diseases and diabetic nephropathy | Significant reduction in adverse cardiovascular events | [11,15,16,17,18,19,20,21,22] |
Multiple system atrophy | Accurate biomarker for MSA when found in low levels in cerebrospinal fluid | [20,23,24,25,26,27,28,29,30] |
Immunological disorders | Significant improvement of the T cell function Reduction of circulating inflammatory markers |
[14,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50] |
Neuropathies | Neuroprotection via Ca2+ buffering and antioxidant activity | [35,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79] |
UVB radiation damage | Treatment of damaged skin | [66,80,81,82,83,84,85] |
Heart failure | Supplementation required for improving patient condition | [82,86,87,88,89,90,91,92,93] |
Barth syndrome and membrane instability-related diseases | CoQ10-based treatment for Barth syndrome patients Development of cholesterol-free liposome-based drug delivery systems |
[94,95,96,97,98,99,100,101,102,103,104,105,106] |
Insulin resistance | Increase in insulin sensitivity by scavenging mitochondrial oxidants | [107,108,109,110,111,112,113,114,115] |
Fibromyalgia | Pain alleviation | [116,117,118,119,120,121] |
Familial hypercholesterolemia and atherosclerosis | Supplementation required for improving patient condition | [122,123,124,125,126] |